The DOI matches its Crossref record.
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety
Open accessAbstract
Background and purpose: The major drug‐metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the activity of these enzymes because of genetic polymorphisms and/or drug–drug interactions is well established. The possible role of an active metabolite in the pharmacodynamics of oxycodone has been questioned and the importance of CYP3A‐mediated effects on the pharmacokinetics and pharmacodynamics of oxycodone has been poorly explored. Experimental approach: We conducted a randomized crossover (five arms) double‐blind placebo‐controlled study in 10 healthy volunteers genotyped for CYP2D6. Oral oxycodone (0.2 mg·kg−1) was given alone or after inhibition of CYP2D6 (with quinidine) and/or of CYP3A (with ketoconazole). Experimental pain (cold pressor test, electrical stimulation, thermode), pupil size, psychomotor effects and toxicity were assessed. Key results: CYP2D6 activity was correlated with oxycodone experimental pain assessment. CYP2D6 ultra‐rapid metabolizers experienced increased pharmacodynamic effects, whereas cold pressor test and pupil size were unchanged in CYP2D6 poor metabolizers, relative to extensive metabolizers. CYP2D6 blockade reduced subjective pain threshold (SPT) for oxycodone by 30% and the response was similar to placebo. CYP3A4 blockade had a major effect on all pharmacodynamic assessments and SPT increased by 15%. Oxymorphone C max was correlated with SPT assessment (ρ S= 0.7) and the only independent positive predictor of SPT. Side‐effects were observed after CYP3A4 blockade and/or in CYP2D6 ultra‐rapid metabolizers. Conclusions and implications: The modulation of CYP2D6 and CYP3A activities had clear effects on oxycodone pharmacodynamics and these effects were dependent on CYP2D6 genetic polymorphism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Callaghan, J. T., Samer, C. F., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2149 · Cited by 434
Self-citationApplications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Self-citationEmerging therapies for patients with symptoms of opioid-induced bowel dysfunction
Leppert, W. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s32684 · Cited by 72
Metadata
- Authors
- Samer, C., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C., Rebsamen, M., Rossier, M., Hochstrasser, D., Dayer, P., & Desmeules, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-05-24
- Volume
- 160
- Issue
- 4
- Pages
- 919-930
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2013235742
- Cited by
- 201
- References
- 0
- FWCI
- 17.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00709.x
- The paper
- Samer, C., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C., Rebsamen, M., Rossier, M., Hochstrasser, D., Dayer, P., & Desmeules, J. (2010). Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00709.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.